“The worst of the U.S. corona-virus outbreak will end by January either with a vaccine or because enough people in the country will have already been infected and have some immunity to it, former Food and Drug Administration Commissioner Dr. Scott Gottlieb told CNBC on Thursday.”
“This will be over by January one way or the other,” he said on “Squawk Box.” “Either we’ll get to a vaccine or we’ll just have spread enough it’s just going to stop spreading efficiently, so we have a short period of time to get through. We should do everything we can to preserve what we want of our way of life over that time period to just get through it.”
other postings / predictions :
False Hope? What Happens If a COVID-19 Vaccine Isn’t Ready by Early Next Year – health news – Dr. Anthony FauciTrusted Source, among others, has stated that the United States should have more than 100 million doses of a potential COVID-19 vaccine by early next year.
However, Fauci and other infectious disease experts caution that this prediction is an aspiration, not a promise.
“We are producing vaccine at risk, which means we are producing it even though we don’t know yet if the vaccine works,” Fauci told Healthline in an interview last Friday. (Health line posted June 2020) full story
Finding a coronavirus vaccine is hard. Getting it to people is a whole other problem
The quest to combat a deadly pandemic is exposing bottlenecks in the pharmaceutical supply chain. The world has neither enough glass vials to house the vaccine nor the facility capacity to fill and package them, experts say.”The demand is going to far outstrip the supply,” Vijay Kumar, an Evercore analyst who focuses on the medical device and life sciences sectors, told CNN Business in an interview.The Covid-19 pandemic has consistently shown what happens when supply chains are blindsided by spikes and drop-offs in demand and how an unexpected bottleneck can affect the integrity of the entire system. CNN full story
As fears of a second wave of Covid-19 weigh on stocks, here’s some potentially good news: A vaccine may be approved before the November election, according to a major biotechnology investing research firm.
The prediction is a big deal for investors for three reasons.
1. It’s credible because it comes from Jefferies, a high-profile brokerage in biotech and pharma that’s wired in to literally hundreds of companies in the group, including the major vaccine developers. Jefferies has nine analysts covering the industry.
2. Food and Drug Administration (FDA) approval of a vaccine ahead of voting could have an impact on the elections, possibly swaying the outcome in favor of President Trump. (Market watch June 2020) Full story